CSPC PHARMA (01093): The Phase I clinical trial of SYH2056 tablets for the treatment of depression has officially launched in China.

CSPC PHARMA (01093) announced that the SYH2056 tablet (the product) developed by the group is intended for the treatment of depression. A Phase I clinical trial (study protocol number: SYH2056-001) evaluating the safety, tolerability, pharmacokinetic characteristics, and food effects of a single oral dose of the product in healthy participants in China has been officially launched. This product is a small molecule 5-HT2A partial agonist developed by the group. While exhibiting partial agonistic activity at the 5-HT2A receptor, the product maintains good synaptic plasticity in neurons; a single dose can demonstrate comparable or superior antidepressant effects to similar products in various animal models. In addition, preclinical studies show a low risk of off-target effects, hallucinations, and drug dependence associated with the product. SYH2056-001 is a Phase I clinical trial assessing the safety, tolerability, pharmacokinetic characteristics, and food effects of a single oral dose of the product in healthy participants in China, primarily aimed at evaluating the safety, tolerability, pharmacokinetics, and the impact on neuropsychiatric status of a single oral administration in healthy participants. Currently, participant recruitment and screening are actively underway.